Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
← catalyst calendarNCT06464692 · readout ≤ 499 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
31actual
Sites
8
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-30 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colorectal Cancer
Intervention
- Drug: Telisotuzumab Adizutecan
Primary outcomes
what the primary-completion date above is the date OFDose-Limiting Toxicity (DLT) of Telisotuzumab Adizutecan in Stage 1
measured Up to 24 Months
Maximum observed plasma or serum concentration (Cmax) of Telisotuzumab Adizutecan Conjugate
measured Up to 24 Months
Time to Cmax (Tmax) of Telisotuzumab Adizutecan Conjugate
measured Up to 24 Months
Area Under the Concentration-Time Curve (AUC) of Telisotuzumab Adizutecan Conjugate
measured Up to 24 Months
Total Antibody of Telisotuzumab Adizutecan
measured Up to 24 Months
Unconjugated Payload of Telisotuzumab Adizutecan
measured Up to 24 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed